Venture Capital

With a historic $1.1B in funding, David Silver's Ineffable Intelligence partners with Google Cloud to build an AI that learns from experience, not just data.

Univest Securities secures $8M for Pop Culture Group via a direct offering. We look under the hood at the deal's mechanics and CPOP's ambitious growth plans.

Great Estate Blockchain divests its main revenue source after a flawed deal structure implodes, leaving the penny-stock firm seeking a new identity.

Adaptive Biotechnologies' new debt offering is more than a financial tune-up; it's a calculated move to sever a costly royalty deal and arm its star MRD division for a separate future.

AIRA ushers in new leadership with Boris Steffen as President, poised to navigate economic turbulence and shape the future of the insolvency profession.

With a new $75M fund, Gutter Capital is doubling down on its 'old school' model: intense operational support for 'overlooked' founders in New York City.

After a $40 billion market collapse, venture capital is back with a new playbook. Anterra Capital’s new fund signals a shift from hype to real-world AI.

Amid a venture capital slowdown, a Philadelphia model is gaining traction by prioritizing discipline over hype. We explore how this ecosystem is making startups investor-ready.

Elysium Health's new Creatine+ isn't just a supplement; it's a signal of a massive structural shift where human vitality becomes a core economic asset.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

Chaka Khan's partnership with HarbourView isn't just a deal; it's a look into the future of music, where finance and artistry create a new kind of legacy.

While firms spend billions on tech, a new book argues the biggest data breaches stem from leadership gaps and process failures. Is your boardroom the real front line?

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

Lundin Gold just spun off its silver asset into a new company, LunR Royalties, rewarding shareholders with a special dividend. What does this mean for both firms?

Amedea Pharma's Medical Innovation Olympics isn't just a contest; it's a data-driven crucible for new treatments, with longevity medicine taking center stage.

Northern 2 VCT holds dividends steady despite an NAV dip, celebrating a major IPO while facing new principal risks from AI and UK tax policy changes.

Dynasty Financial Partners acquires consulting firm Optima Group, betting that a fully integrated platform of tech, capital, and strategy is the future of RIA support.

Despite a dip in NAV, Northern Venture Trust raises £30M and maintains dividends, bracing for the impact of a major VCT tax relief cut on UK startups.

An exclusive Florida summit reveals a power shift in sports finance, where athletes are no longer just players but owners, and family offices are the new kingmakers.

With $850M in new capital, Base10 Partners doubles down on its 'Real Economy AI' thesis, proving that automating traditional industries is venture's next frontier.